iMDx reports Q3 2026 results, FDA review of GraftAssureDx paused on information request
Insight Molecular Diagnostics said the FDA paused its review clock after requesting more data on GraftAssureDx, with a response due before January 21, 2027.
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) reported third quarter 2026 results on November 16, 2026, alongside an update on its lead product, GraftAssureDx, a kidney transplant rejection test under FDA review.
The company said that in late July, the FDA completed the current phase of its substantive review of GraftAssureDx and requested additional information, which the company described as common for a de novo submission.1 It said the request related primarily to the design and analysis of its clinical validation study, with the FDA's preliminary view being that the submitted clinical data did not yet support the proposed intended use.1 The company said it met with the FDA in late September to discuss its approach to the request, and that the agency provided both verbal and written feedback to guide the response.1
iMDx said it expects an independent accuracy study and a pathology slide review to be completed before the end of the year, and expects to submit its complete response before the January 21, 2027 deadline.1 It noted the FDA has a targeted review timeline of 150 days for Class II de novo submissions, that the clock has been paused since the late-July information request, and that it estimates roughly half of the review days remain, with the clock expected to restart once the complete response is submitted.1
On the registry side, the company said its GALACTIC registry study is now enrolling patients, with UCLA Medical Center enrolling the first several.1 It added that related testing revenue is expected to build over coming months as enrollment grows and additional sites are activated.1
Financially, third quarter 2026 revenue was $559,000, compared to approximately $260,000 in Q3 2025, as the company called itself essentially "pre-revenue" while awaiting potential FDA authorization.1 Cash, cash equivalents, and restricted cash stood at $11.8 million at quarter end, down from $18.7 million at the end of the second quarter and $20.2 million at the end of Q3 2025.1 The company said it continues to target outgoing free cash flow of approximately $8 million in the fourth quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.